Showing 5 posts of 5 posts found.


BeiGene’s tislelizumab gets China approval for non-small cell lung cancer

January 14, 2021
BeiGene, Cancer, tislelizumab

BeiGene Ltd has announced that its anti-PD-1 antibody tislelizumab has received approval from the China National Medical Products Administration (NMPA) …


Novartis and BeiGene join forces to develop cancer drug tislelizumab

January 12, 2021
Manufacturing and Production BeiGene, Cancer, Novartis

Novartis has signed a strategic collaboration agreement to in-license tislelizumab from BeiGene Ltd in major markets outside of China, accelerating …


Amgen drops $2.7bn to acquire stake in Chinese biotech in bid to expand in the region

November 1, 2019
Medical Communications, Research and Development, Sales and Marketing Amgen, BeiGene, Cancer, China, deal, oncology, pharma

Amgen has signed an agreement with Chinese biotech BeiGene to acquire a 20.5% stake in the latter, in a bid …


Celgene plays catch up with $1.4 billion immunotherapy deal

July 7, 2017
Medical Communications, Sales and Marketing BeiGene, Celgene, immunotherapy, pd-1

Those commentating on Celgene’s latest deal seem to be equally divided between two camps: it is too much money, too …


BeiGene to develop $330 million biologics plant

March 7, 2017
Manufacturing and Production, Research and Development BeiGene, China, Guangzhou

BeiGene, a Chinese biotech company, and Guangzhou GET Technology Development, an affiliate of Guangzhou Development District, will partner in the …

Latest content